Searchable abstracts of presentations at key conferences in endocrinology

ea0032p853 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease

Newell-Price John , Petersenn Stephan , Pivonello Rosario , Findling James , Fleseriu Maria , Trovato Andrew , Hughes Gareth , Ligueros-Saylan Monica , Biller Beverly

Introduction: Generously supported by IPSEN)-->Measurement of salivary cortisol is a simple, convenient, accurate and reproducible technique with potential value during the diagnosis/management of hypercortisolism. Current analysis evaluates changes in late-night salivary cortisol (LNSC) during pasireotide treatment in patients with Cushing’s disease (CD).Methods: A 12 m, Phase III study enrolled 162 adult...

ea0032p841 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

The benefits of pasireotide in patients with Cushing's disease are not restricted to patients with normalisation of UFC; results from a large, 12-month study

Pivonello Rosario , Petersenn Stephan , Gu Feng , Trovato Andrew , Hughes Gareth , Ligueros-Saylan Monica , Roberto Salgado Luiz , Lacroix Andre , Schopohl Jochen , Biller Beverly

Introduction: Pasireotide normalized or reduced UFC in patients with Cushing’s disease in a large, 12-month study. This analysis evaluates the effects of pasireotide on the signs/symptoms of Cushing’s disease according to the degree of UFC control.Methods: Adult patients (n=162) with persistent/recurrent or de novo Cushing’s disease were randomized to pasireotide 600/900 μg s.c. bid. Dose titration (max: 1200 μg...